The Society for Immunotherapy of Cancer (SITC) published its first clinical practice guideline (CPG) on immunotherapy for the treatment of Non-Small Cell Lung Cancer in the Journal for ImmunoTherapy of Cancer on July 17, 2018. An update to this guideline that will cover Lung Cancer and Mesothelioma is currently in progress.SITC's Cancer Immunotherapy Guidelines program is a collection of CPGs developed by multi-disciplinary panels of experts who draw from their own practical experience as well as evidence in the published literature and clinical trial data to develop evidence- and consensus-based recommendations. SITC uses as a model the Institute of Medicine's 2011 "Standards for Developing Trustworthy Clinical Practice Guidelines" to ensure the recommendations are unbiased, transparent and balanced will aid oncologists in effective clinical decision-making concerning patient selection, toxicity management, response evaluation, and the sequencing or combination of therapies, among other topics. The Non-Small Cell Lung Cancer CPG was developed collaboratively through the efforts of an expert panel that convened to discuss the current therapeutic landscape. This CPG provides recommendations for the use and sequencing of immunotherapies including nivolumab, pembrolizumab, atezolizumab and durvalumab. Additionally, this CPG also covers discussion concerning patient selection, toxicity management and clinical endpoints, and patient quality of life issues.
SITC is pleased to offer free live and on-demand webinars featuring Expert Panel members from SITC's Non-small Cell Lung Cancer Guideline. These educational offerings are designed for healthcare providers who treat cancer patients including oncologists, physicians, disease specialists, registered nurses, nurse practitioners, pharmacists and physician assistants. The live webinars include a dedicated question-and-answer session providing the opportunity for attendees to converse with the faculty and ask questions about the guideline recommendations.
In this introductory webinar, Expert Panel members provide attendees with an overview of the published guideline and highlight selected recommendations that are applicable to some of the most common scenarios clinicians may encounter while treating their patients with immunotherapy. After attending this webinar, learners will be better able to implement immunotherapy treatments effectively and in accordance with the recommendations in the SITC CPG.
Charu Aggarwal, MD, MPH — University of Pennsylvania
Scott J. Antonia, MD, PhD — Duke University School of Medicine
Marianne Davies, DNP, AOCNP — Yale School of Nursing
Steven M. Dubinett, MD — David Geffen School of Medicine at UCLA
Andrea Ferris, MBA — LUNGevity
Patrick Forde, MD — Johns Hopkins University School of Medicine
Edward B. Garon, MD — University of California, Los Angeles
Sarah B. Goldberg, MD, MPH — Yale School of Medicine, Yale Cancer Center
Raffit Hassan, MD — National Institutes of Health
Matthew D. Hellmann, MD — Memorial Sloan Kettering Cancer Center
Fred R. Hirsch, MD, PhD — Icahn School of Medicine at Mount Sinai
Melissa L. Johnson, MD — Sarah Cannon Research Institute
Shakuntala Malik, MD — National Cancer Institute
Daniel Morgensztern, MD — Siteman Cancer Center, Washington University School of Medicine
Joel Neal, MD, PhD — Stanford University
Jyoti Patel, MD — Robert H. Lurie Comprehensive Cancer Center of Northwestern University
David L. Rimm, MD, PhD — Yale University
Sarah Sagorsky, PA-C — Johns Hopkins University School of Medicine
Lawrence H. Schwartz, MD — Columbia University Medical Center
Boris Sepesi, MD, FACS — The University of Texas MD Anderson Cancer Center
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org